Catherine Ellis
Catherine Ellis has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Danny Rischin
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
110 shared publications - Marc Ballas
GSK 20 , Collegeville, Pennsylvania
110 shared publications - Michael Chisamore
13Merck & Co., Inc., Rahway, New Jersey
110 shared publications - Ashleigh Hahn
GSK, Collegeville, Pennsylvania
95 shared publications - Axel Hoos
Scorpion Therapeutics, Boston, Massachusetts
95 shared publications - Christina Blackwell
GSK, Collegeville, Pennsylvania
95 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Annals of Hematology
Dual transfusion independence and spleen volume reduction are associated with overall survival in patients with myelofibrosis treated with momelotinib: post hoc analyses of SIMPLIFY-1 and MOMENTUM
Spleen volume reduction (SVR) and transfusion independence (TI) are associated with improved overall survival (OS) in myelofibrosis, but the joint contribution of these endpoints remains unclear. These post hoc analyses evaluated the association between concurrent SVR and TI at week 24 with OS in patients with primary or post–polycythemia vera/essential thrombocythemia myelofibrosis treated with momelotinib in the phase 3 SIMPLIFY‑1 (JAK inhibitor–naive) and MOMENTUM (JAK inhibitor–experienced) trials. Dual response was defined as joint TI and SVR thresholds of ≥ 35%, ≥ 25%, ≥ 15%, or ≥ 10% from baseline at week 24. Dual SVR + TI responders consistently demonstrated numerically longer OS vs. nonresponders across SVR thresholds. In SIMPLIFY‑1, hazard ratios (HRs) for death ranged from 0.26 (SVR10 + TI, 95% CI 0.16–0.43) to 0.64 (SVR35 + TI, 95% CI 0.38–1.10), with median OS exceeding that of nonresponders (e.g., 120.8 vs. 41.5 months for SVR10 + TI). In MOMENTUM, dual responders similarly showed numerically improved OS, with HRs of 0.33 (SVR10 + TI, 95% CI 0.17–0.65) and 0.32 (SVR35 + TI, 95% CI 0.11–0.88), with median OS not reached in responders (for both SVR10 + TI and SVR35 + TI) vs. 28.7 (nonresponders of SVR10 + TI) or 32.0 months (nonresponders of SVR35 + TI). Patients with both TI and SVR at week 24 demonstrated longer OS across all SVR thresholds evaluated, with the most pronounced separation of survival curves observed at the lowest SVR thresholds (≥ 10% and ≥ 15%). This pattern supports the concept that, in patients treated with momelotinib who achieve or maintain TI, relatively modest SVRs may be sufficient to achieve a survival advantage.
- 8 October 2026
- Published by Springer Nature in Annals of Hematology
Open AccessDual transfusion independence and spleen volume reduction are associated with overall survival in patients with myelofibrosis treated with momelotinib: post hoc analyses of SIMPLIFY-1 and MOMENTUM
Spleen volume reduction (SVR) and transfusion independence (TI) are associated with improved overall survival (OS) in myelofibrosis, but the joint contribution of these endpoints remains unclear. These post hoc analyses evaluated the association between concurrent SVR and TI at week 24 with OS in patients with primary or post–polycythemia vera/essential thrombocythemia myelofibrosis treated with momelotinib in the phase 3 SIMPLIFY‑1 (JAK inhibitor–naive) and MOMENTUM (JAK inhibitor–experienced) trials. Dual response was defined as joint TI and SVR thresholds of ≥ 35%, ≥ 25%, ≥ 15%, or ≥ 10% from baseline at week 24. Dual SVR + TI responders consistently demonstrated numerically longer OS vs. nonresponders across SVR thresholds. In SIMPLIFY‑1, hazard ratios (HRs) for death ranged from 0.26 (SVR10 + TI, 95% CI 0.16–0.43) to 0.64 (SVR35 + TI, 95% CI 0.38–1.10), with median OS exceeding that of nonresponders (e.g., 120.8 vs. 41.5 months for SVR10 + TI). In MOMENTUM, dual responders similarly showed numerically improved OS, with HRs of 0.33 (SVR10 + TI, 95% CI 0.17–0.65) and 0.32 (SVR35 + TI, 95% CI 0.11–0.88), with median OS not reached in responders (for both SVR10 + TI and SVR35 + TI) vs. 28.7 (nonresponders of SVR10 + TI) or 32.0 months (nonresponders of SVR35 + TI). Patients with both TI and SVR at week 24 demonstrated longer OS across all SVR thresholds evaluated, with the most pronounced separation of survival curves observed at the lowest SVR thresholds (≥ 10% and ≥ 15%). This pattern supports the concept that, in patients treated with momelotinib who achieve or maintain TI, relatively modest SVRs may be sufficient to achieve a survival advantage.
- Open Access
- 11 September 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (11) , 2179-2183
Optimized dosing of momelotinib in myelofibrosis through quantitative medicine: a clinical commentary
Historically, dose-finding in oncology drug development has been guided by maximum tolerated dose (MTD) principles, often exposing patients to unnecessary toxicity without achieving additional effi...
- 11 September 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (11) , 2179-2183
Open AccessOptimized dosing of momelotinib in myelofibrosis through quantitative medicine: a clinical commentary
Historically, dose-finding in oncology drug development has been guided by maximum tolerated dose (MTD) principles, often exposing patients to unnecessary toxicity without achieving additional effi...
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of TTD in pain and physical function (mITT population and PD-L1 CPS≥20 subgroup)
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of TTD in pain and physical function (mITT population and PD-L1 CPS≥20 subgroup)
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of AEs by maximum severity grade (Safety population)
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of AEs by maximum severity grade (Safety population)
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Comparison of baseline germline genetic biomarkers between treatment arms (post-hoc analyses)
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Comparison of baseline germline genetic biomarkers between treatment arms (post-hoc analyses)
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Tumor gene expression and genomic profiling (post-hoc analyses)
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Tumor gene expression and genomic profiling (post-hoc analyses)
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Study design. *Patients randomized after the date of DIL who were unable to receive feladilimab/placebo were excluded from the mITT population but included in the safety population; †more than one reason could be selected; AE, adverse event; DIL, Dear Investigator Letter; ITT, intention to treat; mITT, modified ITT.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Study design. *Patients randomized after the date of DIL who were unable to receive feladilimab/placebo were excluded from the mITT population but included in the safety population; †more than one reason could be selected; AE, adverse event; DIL, Dear Investigator Letter; ITT, intention to treat; mITT, modified ITT.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Patient outcomes by baseline ctDNA and molecular response (post hoc analyses). A, PFS Kaplan–Meier curves for the BEP1 stratified by baseline ctDNA. B, PFS treatment responses in patients stratified by baseline ctDNA level, adjusted for PD-L1 and HPV status. C, PFS Kaplan–Meier curves for the BEP2 stratified by molecular responder status at week 15. D, BOR distribution across treatment groups. BEP1 is defined as all patients with a baseline sample, and the BEP2 is defined as all patients with both a baseline and week 15 sample. ctDNA high and low are defined as mVAF ≥ 1.33% and <1.33%, respectively. Molecular responders and nonresponders are defined as patients with a reduction from baseline at week 15 in ctDNA of ≥50% and <50%, respectively. AIC, Akaike information criterion; BOR, best overall response; MNR, molecular nonresponder; MR, molecular responder; PD, progressive disease; SD, stable disease.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Patient outcomes by baseline ctDNA and molecular response (post hoc analyses). A, PFS Kaplan–Meier curves for the BEP1 stratified by baseline ctDNA. B, PFS treatment responses in patients stratified by baseline ctDNA level, adjusted for PD-L1 and HPV status. C, PFS Kaplan–Meier curves for the BEP2 stratified by molecular responder status at week 15. D, BOR distribution across treatment groups. BEP1 is defined as all patients with a baseline sample, and the BEP2 is defined as all patients with both a baseline and week 15 sample. ctDNA high and low are defined as mVAF ≥ 1.33% and <1.33%, respectively. Molecular responders and nonresponders are defined as patients with a reduction from baseline at week 15 in ctDNA of ≥50% and <50%, respectively. AIC, Akaike information criterion; BOR, best overall response; MNR, molecular nonresponder; MR, molecular responder; PD, progressive disease; SD, stable disease.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Baseline demographics and disease characteristics (mITT population).
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Baseline demographics and disease characteristics (mITT population).
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of investigator-assessed best response without confirmation (mITT population and PD-L1 CPS ≥ 20 subgroup).
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of investigator-assessed best response without confirmation (mITT population and PD-L1 CPS ≥ 20 subgroup).